Moderna Inc
MRNA
View Detailed Chart
24.770USD
-0.190-0.76%
Close 11/14, 16:00（ET）Quotes delayed by 15 min
9.69BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-0.76%
5 Days
+0.94%
1 Month
-5.64%
6 Months
+3.12%
Year to Date
-40.43%
1 Year
-37.72%
View Detailed Chart
TradingKey Stock Score of Moderna Inc
Currency: USD Updated: 2025-11-14Key Insights
The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a weak stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Moderna Inc's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
25
analysts
Hold
Current Rating
40.722
Target Price
+63.15%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Moderna Inc Highlights
StrengthsRisks
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.
Fairly Valued
The company’s latest PE is -3.08, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 289.85M shares, decreasing 6.70% quarter-over-quarter.
Held by Baillie Gifford
Star Investor Baillie Gifford holds 21.85M shares of this stock.
Moderna Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Moderna Inc Info
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.
Ticker SymbolMRNA
CompanyModerna Inc
CEOMr. Stephane Bancel
Websitehttps://www.modernatx.com/
Related Instruments
+0.43%
+0.38%
+0.12%
+0.55%
-0.52%
+0.06%
+0.22%
-1.85%
-0.14%
-2.73%
-0.38%
+0.61%
-0.49%
-4.05%
-1.06%
-3.18%
0.00%
-0.21%
-1.06%
+1.82%Popular Symbols
